C4 Therapeutics Announces Pricing of $125 Million Underwritten Offering

Core Viewpoint - C4 Therapeutics, Inc. is raising $125 million through an underwritten offering to fund the next phase of its cemsidomide multiple myeloma development, with potential additional proceeds of up to $225 million [1][5]. Group 1: Offering Details - The offering consists of 21,895,000 shares of common stock and pre-funded warrants to purchase up to 28,713,500 shares of common stock [2]. - The offering is priced at $2.47 per share of common stock and accompanying warrants, and $2.4699 per pre-funded warrant and accompanying warrants [4]. - The total gross proceeds from the offering are expected to be $125 million, with a potential total of $349.7 million if all warrants are exercised [5]. Group 2: Use of Proceeds - The net proceeds from the offering will primarily fund ongoing and planned clinical trials of cemsidomide, other research and development activities, and general corporate purposes [6]. Group 3: Company Overview - C4 Therapeutics is a clinical-stage biopharmaceutical company focused on targeted protein degradation science, aiming to develop new medicines for difficult-to-treat diseases [11]. - The company utilizes its TORPEDO® platform to design and optimize small-molecule medicines, which are intended to degrade disease-causing proteins and improve patient outcomes [11].